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Increased serum strontium levels in dialysis patients: An epide- We recently determined various trace element concen-
miological survey. trations in 100 bone biopsies of dialysis patients present-
Background. We previously reported on increased bone ing with various types of renal osteodystrophy. These
strontium levels in dialysis patients with osteomalacia versus
bone biopsies had previously been taken in the contextthose presenting other types of renal osteodystrophy. A causal
of studies of the noninvasive diagnosis of adynamic androle of strontium in the development of osteomalacia was es-
tablished in a chronic renal failure rat model. aluminum (Al)-related bone disease [1, 2]. Histological/
Methods. To further elucidate the latter issue and to find chemical examination of the 100 bone biopsies revealed
out whether dialysis patients from particular centers/countries bone strontium (Sr) levels, as well as Sr/calcium (Ca)
are at an increased risk for strontium accumulation, a world-
ratios to be increased in osteomalacic patients. Bone Srwide multicenter study was established. In total, 834 patients
levels were not only elevated compared to individualsfrom 34 dialysis centers in 23 countries were included. In each
with a normal bone histology, but also in comparison toof the patients, a serum sample was taken for strontium deter-
mination, and water and dialysate samples were taken at the all other types of renal osteodystrophy. Bone Sr and
various steps of the water purification process. For each patient bone Ca levels correlated with each other. The slope of
clinical data and for each center dialysis modalities were re- the linear regression curve correlating these parameters
corded.
was much steeper in the osteomalacic group as comparedResults. Strontium levels in serum of dialysis patients showed
to the other types of renal osteodystrophy. Furthermore,major differences between the various centers, ranging from
mean values of 25 6 8 mg/liter in the center with the lowest we found bone Sr levels to correlate with bone Al levels
level up to 466 6 90 mg/liter in the center with the highest in the group of patients with osteomalacia, suggesting
concentration. It is of interest that these high levels were mainly that the development of this disease could be the result
found in developing countries. Furthermore, our data point
of a multi-element effect [3]. A causal role of Sr in thetoward a role of the final dialysate in the accumulation of the
development of osteomalacia was established in an ex-element, as indicated by the strong correlation (r 5 0.74, P ,
perimental study. Here, oral administration of Sr to a0.001) between mean serum and dialysate strontium levels. As
the high tap water concentration of strontium was adequately chronic renal failure rat model resulted in the develop-
reduced during the water purification process, contamination of ment of distinct osteomalacic lesions. Of interest was that
the final dialysis fluid occurred by the addition of concentrates in this study, rats loaded with Al developed adynamic
contaminated with strontium. Besides the dialysate, other fac-
bone, whereas in the group of animals loaded with bothtors, such as duration of dialysis, vitamin D supplements, or
Sr and Al, some rats developed adynamic bone, whereastypes of phosphate binders, played a less important role in the
accumulation of the element. in others, a more severe osteomalacia occurred [4].
Conclusions. Data of this multicenter study indicate patients Notwithstanding its abundance in nature, little is known
of particular dialysis centers to be at an increased risk for about the metabolism of Sr and whether or not it is
strontium accumulation, the clinical consequence of which is
essential for humans. Sr is a natural constituent of foodunder current investigation.
and beverages. Meat, poultry, vegetables, and fruit con-
tain relatively low amounts of the element, but in cereals,
grains, and seafood, the element may be present at con-Key words: osteomalacia, aluminum, dialysate, renal osteodystrophy,
chronic renal failure. centrations up to 25 mg/kg. Hence, the Sr content of the
human diet and the daily intake of the element varies
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the main route of entry [8]. Strontium is mainly excreted 1 Japanese center, and 6 African centers were included
in this multicenter study. Serum samples were takenby the kidney [6], suggesting that patients with renal
insufficiency are at an increased risk for accumulation before the start of the HD session. Besides the Sr level
in serum, we also determined the element’s concentra-of the element. The distribution of Sr is similar to Ca,
with 99% of the element being stored in bone [9]. Some tion in tap water, water samples taken at several points
of the water-purification process, and the final dialysispublished data suggest that in addition to effects on bone
formation [10, 11], resorption [10–12], and mineraliza- fluid. In addition to Sr, the Al concentration in all serum
and water samples, as well as in the final dialysis fluid,tion [10, 11, 13, 14], there may be interference by Sr with
Ca metabolism [6, 9] and vitamin D synthesis [15, 16]. was determined also.
A questionnaire with personal and clinical data fromThe proposed effects of Sr on bone might be of particular
interest in patients with chronic renal failure, especially each dialysis patient was completed, together with infor-
mation about the dialysis modalities of each center. Thethose treated by dialysis. Indeed, Sr may accumulate in
these patients because of the impaired renal function, dialysis population had a median age of 56 years (range
5 to 96), a median time on dialysis of 36 months (rangethe contamination of phosphate binders, and when
treated by dialysis, the use of Sr containing parenteral 1 to 300), and a 55% male predominance. A Sr-rich diet
(seafood and grains) was ingested by 65% of the popula-and dialysis fluids [17, 18]. The poverty of information
regarding the element’s metabolism is mainly due to tion. Concerning the phosphate binders: 56.6% of the
patients took only CaCO3; 4.9% of the subjects took onlythe lack of reliable methodologies able to accurately
determine and localize the element at the relative low Al(OH)3, and 13.0% of the total population took a com-
bination of Al(OH)3 and CaCO3 and/or other phosphatelevels in which it is present in the human body.
To support the previous findings of the bone biopsy binders. Some of the patients (25.5%) took no phosphate
binder or none of the types of phosphate binders westudy, a worldwide multicenter study was established to
check whether certain dialysis patients or centers are at asked about in our questionnaire. Vitamin D supplements
were used by 57.2% of the patients. A majority of thean increased risk for Sr accumulation, and to study which
factors are responsible for the accumulation of the ele- patients (57.1%) received erythropoietin (EPO) treat-
ment, and 54.5% underwent transfusions. Only 1.6% ofment within this population. In this study using a recently
developed electrothermal atomic absorption method the patients were treated by deferoxamine (DFO) ther-
apy, whereas 2.6% had undergone a parathyroidectomy.[19], (a) serum Sr levels in subjects with normal renal
function, preterminal renal failure, and hemodialysis Strontium and Al in serum, water, and dialysis fluids
were analyzed using a Zeeman 3030 atomic absorption(HD) were determined and compared with each other,
(b) serum Sr levels of dialysis patients coming from dif- spectrometer equipped with an HGA-600 graphite fur-
nace, an AS-60 autosampler, and an Anadex DP-9500Bferent centers located in various countries were com-
pared, (c) the efficacy of the water treatment procedure silent scribe printer, all from Perkin-Elmer (Norwalk,
CT, USA). To determine Sr, all samples were dilutedin the removal of Sr during the preparation of the dialysis
fluids in the participating centers was checked, and (d) fourfold in a solution of 0.5 ml/liter Triton X-100 and 1
ml/liter HNO3. Aluminum in serum was determined afterthe possible role of various factors in the accumulation
of the element was studied. a 1:3 dilution of the samples in reversed osmosis (RO)
water. Interassay coefficient of variance (CV) was ,6%
(N 5 12, N 5 10, respectively), and the recovery of
METHODS
added analyte was close to 100% for all of the biological
Patients matrices under study. Methods for the determination of
Sr and Al have been described by us in detail previouslySubjects with normal renal function. Serum Sr levels
were determined in 24 subjects with normal renal func- [19, 20]. In order to reduce the risk for contamination,
Sr- and Al-free material for sampling and sample storagetion who had a median age of 33 years (range 22 to 40).
Thirty-three percent were male subjects. was sent to each of the participating centers. All serum,
water, and dialysate analyses were performed in a singlePatients with stable renal failure. In 75 patients with
stable chronic renal failure and who were not yet on laboratory, that is, the Department of Nephrology/Hy-
pertension of the University of Antwerp.dialysis, we also determined serum Sr levels. Forty-eight
percent of the patients in this group were male; the median
Statisticsage of these patients was 54 years (range 18 to 86). Based
on the creatinine clearance, patients were divided into Data were analyzed using the statistical package SPSS
for Windows. Data are expressed as mean 6 sd. Univari-two groups (creatinine clearance , and .50 ml/min).
Patients treated by HD. Eight hundred and thirty-four ate analysis was performed with t-test and chi-square test.
The a priori level of significance was set at P # 0.05.HD patients coming from 17 European centers, 9 South
and Central American centers, 1 Middle-Eastern center, For multivariate analysis, multiple linear regression and
Schrooten et al: Strontium in dialysis patients1888
levels. Figure 4 shows the mean serum Sr levels in the
South and Central American dialysis centers that partici-
pated in the multicenter study. Although most dialysis
centers in this region have increased Sr levels, we cannot
generalize this because levels in both Chile and Argen-
tina are comparable to the concentrations of the element
found in Western countries.
Another interesting finding was that in the high-Sr
group, increased Sr levels were accompanied by in-
creased levels of Al, that is, 72 6 63 mg/liter compared
with 19 6 22 mg/liter in the low-Sr group. Serum Ca was
significantly decreased in the high-Sr group (4.35 6 0.57
mEq/liter) in comparison to the low-Sr group (4.65 6
0.67 mEq/liter; Fig. 5). Also in Figure 5, the differences
in personal and clinical factors between both groups are
Fig. 1. Serum strontium (Sr) levels in subjects with various degrees of shown. Multivariate analysis of all of these data indicates
renal function. *P , 0.001 vs. normal renal function; 8P , 0.001 vs. these factors can explain 20% of the differences in serum
creatinine clearance .50.
Sr levels between both groups.
Out of this relatively small percentage, it is obvious
that other factors must play a role in the accumulation
of Sr in dialysis patients. To further explain this issue,logistic regression were used. The squared correlation
we assessed whether the observed differences betweencoefficient (R2) was calculated for evaluating the explained
the high and low Sr groups could be due to center-to-proportion of variability in a model. Odds ratios and
center variations in either tap water or dialysate. As-95% confidence intervals (95% CI) were estimated using
sessing the evolution of Sr levels during the various stepsthe exp (B) of the logistic regression equation.
of the water purification process, data indicated Sr levels
in the tap water to differ greatly from center to center.
RESULTS During the water purification process, however, Sr was
The mean 6 sd serum Sr level in individuals with removed adequately from the water in both groups (Fig. 6).
normal renal function was 14 6 7.6 mg/liter. In the group In the low-Sr centers, this results in a low concentration
of patients with a creatinine clearance of more than 50 of the element in the final dialysis fluid. In the high-Sr
ml/min, the mean serum Sr level was 28 6 15 mg/liter. group, however, an increase in the Sr concentration be-
In the group of patients with preterminal renal failure tween points 4 (after reversed osmosis) and 5 (inlet arti-
(creatinine clearance ,50 ml/min), the mean serum Sr ficial kidney) of the water treatment process was noted,
level was 52 6 21 mg/liter. The significant increase (P , resulting in an increased concentration of the element
0.0001) of the serum Sr level with decreasing renal func- in the final dialysis fluid. It can be assumed that this accu-
tion is shown in Figure 1. mulation is due to the addition of concentrates contami-
The overall mean 6 sd serum Sr level of the HD nated with Sr. Indeed, analysis of the concentrates used
patients under study was 95 6 103 mg/liter. A center-to- in certain dialysis centers of the high-Sr group revealed
center comparison of the mean serum Sr level of all these solutions to be contaminated with Sr. Interestingly,
dialysis patients indicated significant differences ranging the contamination occurred only in acetate-based con-
from a mean 6 sd value of 25 6 8 mg/liter in the center centrates (up to 15750 mg/liter; undiluted concentrate),
with the lowest value up to 466 6 90 mg/liter (P , 0.0001) whereas Sr levels in bicarbonate-based concentrates
in the center with the highest level (Fig. 2). According were below the analytical detection limit (,3 mg/liter).
to the mean Sr level, the dialysis centers can be catego- A strong correlation (r 5 0.74, P , 0.001) between mean
rized into two groups: a first group of centers with Sr serum and dialysate Sr levels was noted. When the Sr
levels below 100 mg/liter (low Sr group, 42 6 19 mg/liter) concentration in the final dialysis fluid was assessed in
and a second group of centers with levels above 100 mg/ a multivariate model, it explained 50% of the difference
liter (high Sr group, 231 6 104 mg/liter). Of interest was in Sr levels between both groups. Interestingly, when
that all dialysis centers in the latter group were located considering only the high-Sr group, other factors also
in developing countries. As shown in Figure 3, the distri- seem to play a substantial role in the accumulation of
bution of the serum Sr levels in both groups indicates the element, specifically, the serum Ca concentration,
only a very small overlap (0.72%) between groups. These the use of vitamin D supplements, and the consumption
data document that nearly all patients from dialysis cen- of seafood contributed to 43.1% of the variation in serum
Sr levels between dialysis patients within the high-Srters in the high Sr group will have increased serum Sr
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Fig. 2. Mean serum strontium (Sr) levels of
dialysis patients from the different dialysis
centers.
DISCUSSION
As we previously reported, in a histological/chemical
survey of 100 bone biopsies from dialysis patients origi-
nating from several centers in various countries, in-
creased Sr concentrations as well as Sr/Ca ratios were
observed in the bone of patients suffering from osteoma-
lacia as compared with all other types of renal osteodys-
trophy [3]. Interestingly, a recent epidemiological study
in Turkey demonstrated a significantly higher prevalence
of the clinical diagnosis of rickets in children with normal
renal function who were living in a region with a high
soil Sr content and where nutrition was mainly based on
cereals as compared with that in children living in a low
soil Sr region [21]. Experimentally, it has been shown
that administration of Sr to animals with normal renal
function may result in a bone lesion with a histological
resemblance to that seen in vitamin D-deficient rickets
[22]. However, the so-called Sr-induced rickets [23, 24]
differs from Ca- or phosphorus-deficiency rickets in that
vitamin D supplements do not correct the lesion [24, 25].
In an experimental study in chronic renal failure rats
loaded with Sr, we could also demonstrate the presence
of histological lesions that were highly comparable with
the histological features of osteomalacia seen in dialysis
patients [4].
Our results clearly show that serum Sr levels are in-Fig. 3. Distribution of serum strontium (Sr) levels in the low-Sr group
creased in subjects with decreasing renal function, asversus the high-Sr group. There were 599 low-Sr patients [outliers $100
mg/liter: 0.15% (N 5 3: 105, 106, 155 mg/liter)] and 235 high-Sr patients compared with individuals with normal renal function.
[outliers #100 mg/liter: 1.3% (N 5 3: 37, 56, 86 mg/liter)]
This is not unexpected, as the element is mainly excreted
by the kidney.
As early as 1973 using x-ray fluorescence, Rudolph,
Alfrey, and Smythe noted distinctly (five- to eightfold)group. No correlation was present between Sr and Al
increased Sr concentrations in skeletal muscle of dia-within the high-Sr group, indicating that in a number of
lyzed uremics compared with those of nondialyzed indi-these centers, high Sr levels were associated with low
levels of Al. viduals and controls that they suggested to originate from
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Fig. 4. Serum Sr levels in the South and Cen-
tral American dialysis centers.
Fig. 5. Patient characteristics in the high-Sr
and low-Sr groups.
the use of untreated high Sr tap water in the region of high-Sr group, besides the mean Sr levels, mean Al levels
were also increased as compared with the low-Sr group.Denver that was used to prepare the dialysis fluid [26].
At that time, they suggested that in addition to Al, Sr Data of this multicenter study indicate that patients
of particular dialysis centers are at an increased risk formight play a role in the development of renal osteodys-
trophy in dialysis patients. A contributive role for Sr and Sr accumulation. We found Sr levels in dialysis patients
to differ significantly from center to center, as well asAl in the development of dialysis osteomalacia was also
suggested by Canavese et al [17]. In this respect, epidemi- from country to country. These great variations in Sr
levels appeared to be mainly due to the use of Sr-contam-ological findings of our bone biopsy study, demonstrating
a good correlation between Al and Sr in the osteomalacic inated dialysis fluids. High Sr levels in the dialysate
seemed to originate from the addition of Sr-containingpatients but not in those presenting the other types of
renal osteodystrophy, are of particular interest [3]. These concentrates, particularly acetate-based concentrates,
which are added to prepare the final dialysis fluids. Otherfindings could be confirmed in our recent epidemiological
survey, where in the serum of dialysis patients from the factors, such as time on dialysis, vitamin D supplements,
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of increased bone Sr levels. As noted in this study, all
patients of that particular center also have increased
serum Sr levels, which appeared to be due to the use of
a high Sr dialysate (as high as 243 mg/liter). Hence, these
data indicate that dialysis patients treated with Sr con-
taminated dialysis fluids are at an increased risk for Sr
accumulation and perhaps the development of osteoma-
lacia. Further studies are necessary, however, to clarify
the relationship between Sr and osteomalacia.
Data of this multicenter study allow us to conclude
that patients of particular dialysis centers are at an in-
creased risk for Sr accumulation, which appears to be
mainly due to Sr contamination of the dialysis fluid. To
what extent this Sr accumulation has clinical conse-
quences remains to be elucidated.
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